PRIMARY CHEMOTHERAPY TO AVOID MASTECTOMY IN TUMORS WITH DIAMETERS OF 3 CENTIMETERS OR MORE

被引:484
作者
BONADONNA, G
VERONESI, U
BRAMBILLA, C
FERRARI, L
LUINI, A
GRECO, M
BARTOLI, C
DEYOLDI, GC
ZUCALI, R
RILKE, F
ANDREOLA, S
SILVESTRINI, R
DIFRONZO, G
VALAGUSSA, P
机构
[1] Division of Medical Oncology, Istituto Nazionale Tumori, Milan 20133
关键词
D O I
10.1093/jnci/82.19.1539
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In 165 women with breast cancer who were candidates for mastectomy because the largest diameter of the tumor was 3 cm or more, we administered primary chemotherapy in the attempt to substitute conservative for mutilating surgery. We then systematically quantitated tumor reduction by clinical, radiologic,0.0. and histopathologic evaluations. Five consecutive groups of 33 patients received cyclophosphamide, methotrexate, and fluorouracil (CMF); fluorouracil, doxorubicin (Adriamycin), and cyclophosphamide (FAC); or fluorouracil, epirubicin, and cyclophosphamide (FEC). The regimens for the five groups were as follows: group 1, three cycles of CMF; group 2, four cycles of CMF; group 3, three cycles of FAC; group 4, four cycles of FAC; and group 5, three cycles of FEC. In response to primary chemotherapy, 157 of the 161 assessable patients showed measurable tumor shrinkage; progressive disease was documented in four. Tumor shrinkage to less than 3 cm was documented in 127 (81%) of the 157 women subjected to surgery, thus allowing a breast-saving procedure, rather than modified radical mastectomy, in these 127 women. Histopathologic complete remission was documented in seven patients. Tumor response was unrelated to age, menopausal status, DNA content (ploidy), (3H)thymidinelabeling index, drug combination used, or number of treatment cycles in excess of three. The degree of response was inversely proportional to the initial tumor size, and the frequency of response was greater in receptor-negative tumors. Severe vomiting and hair loss were less frequent with CMF than with anthracycline-containing regimens, and the frequency of severe leukopenia and thrombocytopenia was minimal. Our results challenge the classical indication for primary mastectomy by showing that use of full-dose primary chemotherapy, sequentially combined with conservative surgery and radiation, can offer an effective and safe alternative to women concerned about the preservation of body integrity. [J Natl Cancer Inst 82: 1539-1545, 1990] © 1990 Oxford University Press.
引用
收藏
页码:1539 / 1545
页数:7
相关论文
共 23 条
[1]  
BEAHRS OH, 1988, MANUAL STAGING CANCE
[3]   COMBINATION CHEMOTHERAPY AS AN ADJUVANT TREATMENT IN OPERABLE BREAST-CANCER [J].
BONADONNA, G ;
BRUSAMOLINO, E ;
VALAGUSSA, P ;
ROSSI, A ;
BRUGNATELLI, L ;
BRAMBILLA, C ;
DELENA, M ;
TANCINI, G ;
BAJETTA, E ;
MUSUMECI, R ;
VERONESI, U .
NEW ENGLAND JOURNAL OF MEDICINE, 1976, 294 (08) :405-410
[4]  
FELDMAN LD, 1986, CANCER RES, V46, P2578
[5]   5-YEAR RESULTS OF A RANDOMIZED CLINICAL-TRIAL COMPARING TOTAL MASTECTOMY AND SEGMENTAL MASTECTOMY WITH OR WITHOUT RADIATION IN THE TREATMENT OF BREAST-CANCER [J].
FISHER, B ;
BAUER, M ;
MARGOLESE, R ;
POISSON, R ;
PILCH, Y ;
REDMOND, C ;
FISHER, E ;
WOLMARK, N ;
DEUTSCH, M ;
MONTAGUE, E ;
SAFFER, E ;
WICKERHAM, L ;
LERNER, H ;
GLASS, A ;
SHIBATA, H ;
DECKERS, P ;
KETCHAM, A ;
OISHI, R ;
RUSSELL, I .
NEW ENGLAND JOURNAL OF MEDICINE, 1985, 312 (11) :665-673
[6]   1-PHENYLALANINE MUSTARD (L-PAM) IN MANAGEMENT OF PRIMARY BREAST-CANCER - REPORT OF EARLY FINDINGS [J].
FISHER, B ;
CARBONE, P ;
ECONOMOU, SG ;
FRELICK, R ;
GLASS, A ;
LERNER, H ;
REDMOND, C ;
ZELEN, M ;
BAND, P ;
KATRYCH, DL ;
WOLMARK, N ;
FISHER, ER .
NEW ENGLAND JOURNAL OF MEDICINE, 1975, 292 (03) :117-122
[7]   8-YEAR RESULTS OF A RANDOMIZED CLINICAL-TRIAL COMPARING TOTAL MASTECTOMY AND LUMPECTOMY WITH OR WITHOUT IRRADIATION IN THE TREATMENT OF BREAST-CANCER [J].
FISHER, B ;
REDMOND, C ;
POISSON, R ;
MARGOLESE, R ;
WOLMARK, N ;
WICKERHAM, L ;
FISHER, E ;
DEUTSCH, M ;
CAPLAN, R ;
PILCH, Y ;
GLASS, A ;
SHIBATA, H ;
LERNER, H ;
TERZ, J ;
SIDOROVICH, L .
NEW ENGLAND JOURNAL OF MEDICINE, 1989, 320 (13) :822-828
[8]  
FORREST APM, 1986, LANCET, V2, P840
[9]   OSTEO-SARCOMA - 15 YEARS LATER [J].
GOORIN, AM ;
ABELSON, HT ;
FREI, E .
NEW ENGLAND JOURNAL OF MEDICINE, 1985, 313 (26) :1637-1643
[10]  
HELLMAN S, 1989, CANCER PRINCIPLES PR, P1696